NCCN Guidelines® Insights - Primary Cutaneous Lymphomas, Version 2.2020
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement.
Category
  • Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Lymphocytic Leukemia
The management of histologic transformation of CLL to aggressive lymphomas remains an unmet clinical need since the standard of care is not established. Treatment selection for patients with CLL without del(17p)/TP53 mutation should be individualized based patient’s age, performance status, comorbid conditions, as well as the agent’s toxicity profile. Oncologists and hematologists need to understand the unique challenges associated with the management of histologic transformation of CLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Rectal Cancer
The determination of an optimal treatment plan for patients with rectal cancer is a complex process that is reliant on balancing the potential risks and benefits of each treatment option based on an individual patient’s characteristics. Clinicians must be educated about on emerging approaches to personalized treatment for patients with rectal cancer so that the most appropriate treatment options can be offered to each patient.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Chronic Lymphocytic Leukemia Patient Management Simulator
Recent advances in understanding the biology of chronic lymphocytic leukemia (CLL) have resulted in the development of novel therapies targeting key signaling pathways involved in the pathogenesis of this disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Enduring Activity
Credits
Talking to Patients about Cancer Treatment, Risk Factors, and Treatment Cessation during the COVID-19 Pandemic
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
Many new options exist for the treatment of advanced non-small cell lung cancer (NSCLC) in addition to traditional platinum-based chemotherapy. Pharmacists should be aware of the new data and recommendations for immunotherapies and targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies; therefore, pharmacists should educate patients about the possibility of adverse events and the need to report symptoms to their health care teams to avoid severe complications.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Role of the Pharmacist in Smoking Cessation and Education of Patients with Cancer
In order to improve smoking cessation efforts, health care providers need to understand options for smoking cessation therapy as well as the clinical data supporting these interventions. Pharmacists can play a critical role in patient education, therapy recommendations, and therapy management for smoking cessation.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Cervical Cancer, Version 1.2020
These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.
Category
  • Cervical Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Rectal Cancer, Version 6.2020
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines.
Category
  • Rectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages